[ad_1]
A new study confirms the positive effect of using the active ingredient in the treatment of patients with COVID-19. It took place during the first wave of a pandemic right in the epicenter of the disease, in the Italian region of Lombardy, most affected by SARS-CoV-2. It has been performed on patients who have been prescribed erdosteine after being discharged from the hospital and has shown this they significantly improved the quality of life parameters associated with health and shortness of breath.
Cough medicine
According to the adc.sk website, an over-the-counter mucolytic drug database with the active ingredient erdosteine is currently available on the market which, while being one of the expectoration drugs, also has an antibacterial effect. Early use of erdosteine can therefore prevent the use of antibiotics.
An Italian study opens up new perspectives on the use of erdosteine in patients with COVID-19. This is most likely due to the multifactorial mechanism of action (antioxidant, anti-inflammatory, double antibacterial and mucomodulator) and the ability to increase endogenous levels of glutathione, an important natural antioxidant. This could result in a blockage of the spread of the virus in the lungs and a consequent faster recovery of treated patients.
“Erdostein is an interesting molecule that has so far found its application in the management of numerous acute and chronic respiratory diseases, both infectious and non-infectious. Given the complexity of the effects of this molecule, its use in the treatment and recovery of COVID-19 patients with respiratory symptoms can also be envisaged. We will certainly be looking forward to further observations and clinical studies, “Evaluates Prof. MUDr. Miloš Jeseňák, PhD., From the Department of Clinical Immunology and Allergology, Martin University Hospital.
This is the first study to record quality of life details in patients with COVID-19. Its full results have been published in the prestigious Multidisciplinary Respiratory Medicine journal. Erdostein is an original molecule discovered and developed in Italy. It is indicated for the treatment of acute and chronic respiratory diseases, including chronic obstructive pulmonary disease. In Slovakia, the erdostein molecule is also available in the form of over-the-counter granules. The great news is that, according to the available information, it could also be useful in the fight against COVID-19, especially in the supportive treatment of respiratory symptoms of this infection.
.
[ad_2]
Source link
